NCT04507269View on ClinicalTrials.gov

Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 18, 2020

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions
Hepatitis B, Chronic
Interventions
DRUG

VIR-2218

VIR-2218 given by subcutaneous injection

DRUG

Placebo

Saline given by subcutaneous injection

Trial Locations (2)

Unknown

Investigative Site, Beijing

Investigative Site, Changchun

Sponsors

Collaborators (1)

Alnylam Pharmaceuticals
All Listed Sponsors
collaborator

Vir Biotechnology, Inc.

INDUSTRY

collaborator

Alnylam Pharmaceuticals

INDUSTRY

lead

Brii Biosciences Limited

INDUSTRY